bimagrumab semaglutide combination trial Eli Lilly's Next-Gen Obesity Therapies: A New Era of Clinical Dominance?

The “muscle tax” might finally have a solution. GLP-1s changed obesity treatment. But losing muscle was always the tradeoff. New Phase 2 data on bimagrumab + semaglutide shows we might not have

29.94

★★★★☆4.8 (126)

Results of “BELIEVE” trial redefine the rules for GLP1RA therapies: lose fat, keep muscles. + Trial tested semaglutide (Wegovy) with Bimagrumab, a novel monoclonal antibody treatment treatment for preserving muscle + 22 %

28.12

★★★★★4.9 (98)

Bimagrumab-Semaglutide Combination Achieves Significant Weight Loss While Preserving Muscle Mass

26.54

★★★★★5.0 (157)

Regeneron's Semaglutide + Trevogrumab Combination: A Game-Changer in Obesity and Metabolic Disease?

21.15

★★★★★4.7 (84)

A phase 2 clinical trial has demonstrated that bimagrumab, when combined with semaglutide, resulted in significant weight loss for trial participants while maintaining lean muscle mass – suggesting a promising approach for

20.52

★★★★★4.9 (203)

💪 Lose fat, keep the muscle! The BELIEVE Phase 2 trial shows that combining Bimagrumab with Semaglutide leads to 17.8 kg weight loss while preserving lean mass. A game-changer for healthy, sustainable

28.73

★★★★★5.0 (176)

Obesity trials are evolving 👇 New Phase 2 data (Nature Medicine, BELIEVE trial) evaluates bimagrumab ± semaglutide—and highlights a shift beyond weight loss alone. • Focus on fat vs. lean mass •

27.79

★★★★★4.8 (132)